Related Experiment Video

Updated: Aug 17, 2026

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

Antisense oligonucleotides as therapeutics for hyperlipidaemias

Rosanne M Crooke1

  • 1Isis Pharmaceuticals, Inc., 1896 Rutherford Avenue, Carlsbad, CA 92008, USA. rcrooke@isisph.com

Expert Opinion on Biological Therapy
|July 16, 2005
PubMed

Insights

New antisense oligonucleotide (ASO) therapies offer a promising approach to treating hyperlipidaemia, a major risk factor for coronary heart disease (CHD). These novel agents target cholesterol and triglyceride homeostasis, potentially improving outcomes for high-risk patients.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Genetics

Background:

  • Hyperlipidaemia, characterized by elevated low-density lipoprotein cholesterol (LDL-C) or triglycerides (TGs), is a primary risk factor for coronary heart disease (CHD).
  • Despite existing antihyperlipidaemic agents, many high-risk patients fail to achieve lipid goals, necessitating novel therapeutic strategies.
  • Antisense oligonucleotides (ASOs) emerge as a potential new class of drugs for managing hyperlipidaemia.

Purpose of the Study:

  • To describe the antisense technology platform for hyperlipidaemia treatment.
  • To highlight the advantages of ASOs in managing cholesterol and triglyceride homeostasis.
  • To review current research on ASOs for hyperlipidaemia.

Main Methods:

  • ASOs are designed to specifically inhibit novel targets involved in lipid metabolism.
  • The technology platform focuses on selective gene silencing.
  • Research involves preclinical and clinical investigations of ASO efficacy.

Main Results:

  • ASOs demonstrate potential for targeted inhibition of key molecules in cholesterol/TG pathways.
  • This approach offers a new therapeutic avenue for diverse hyperlipidaemia causes.
  • Early research indicates promise for ASOs as monotherapy or combination agents.

Conclusions:

  • Antisense oligonucleotide technology represents a significant advancement in hyperlipidaemia treatment.
  • ASOs offer a targeted and potentially more effective approach to managing lipid disorders.
  • Further research and clinical application of ASOs are warranted for improving cardiovascular health.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...